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Purpose: Early and accurate localization of lesions in patients with biochemical recurrence (BCR) of prostate cancer may
guide salvage therapy decisions. The present study, 18F-Fluciclovine PET/CT in biochemicAL reCurrence Of Prostate caNcer
(FALCON; NCT02578940), aimed to evaluate the effect of 18F-fluciclovine on management of men with BCR of prostate
cancer.
Methods and Materials: Men with a first episode of BCR after curative-intent primary therapy were enrolled at 6 UK
sites. Patients underwent 18F-fluciclovine positron emission tomography/computed tomography (PET/CT) according to
standardized procedures. Clinicians documented management plans before and after scanning, recording changes to
treatment modality as major and changes within a modality as other. The primary outcome measure was record of
a revised management plan postscan. Secondary endpoints were evaluation of optimal prostate specific antigen
(PSA) threshold for detection, salvage treatment outcome assessment based on 18F-fluciclovine-involvement, and
safety.
Results: 18F-Fluciclovine was well tolerated in the 104 scanned patients (median PSA Z 0.79 ng/mL). Lesions were
detected in 58 out of 104 (56%) patients. Detection was broadly proportional to PSA level; 1 ng/mL, 1 out of 3 of
scans were positive, and 93% scans were positive at PSA >2.0 ng/mL. Sixty-six (64%) patients had a postscan man-
agement change (80% after a positive result). Major changes (43 out of 66; 65%) were salvage or systemic therapy to
watchful waiting (16 out of 66; 24%); salvage therapy to systemic therapy (16 out of 66; 24%); and alternative
changes to treatment modality (11 out of 66, 17%). The remaining 23 out of 66 (35%) management changes were
modifications of the prescan plan: most (22 out of 66; 33%) were adjustments to planned brachytherapy/radiation ther-
apy to include a 18F-fluciclovine-guided boost. Where 18F-fluciclovine guided salvage therapy, the PSA response rate
was higher than when 18F-fluciclovine was not involved (15 out of 17 [88%] vs 28 out of 39 [72%]).
Conclusions: 18F-Fluciclovine PET/CT located recurrence in the majority of men with BCR, frequently resulting in
major management plan changes. Incorporating 18F-fluciclovine PET/CT into treatment planning may optimize target-
ing of recurrence sites and avoid futile salvage therapy.  2020 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Prostate cancer is the most common cancer among males in
the United Kingdom, with around 47,600 new cases diag-
nosed in 2016.1 Recently reported UK prospective data
from 1643 low-intermediate risk patients with prostate
cancer show a low event rate after 10 years’ follow-up.2
Progression to metastatic disease was more common
among patients receiving watchful waiting (5.6%) than
among those receiving active treatment, although rates
postprostatectomy (2.4%) and posteradiation therapy were
similar (2.7%). However, as reported by current European
Association of Urology (EAU) guidelines,3 between 27%
and 53% of all patients undergoing initial therapy with
radical prostatectomy or radiation therapy will experience
biochemical recurrence (BCR) characterized by rising
prostate-specific antigen (PSA). Although this BCR may be
prolonged and will not necessarily lead to clinically
apparent metastatic disease, reports suggest that approxi-
mately 25% of patients with BCR progress to metastatic
disease, which is associated with significantly increased
morbidity and mortality.4,5
Early and accurate localization of lesions in patients
with suspected BCR facilitates treatment when tumors are
small and most amenable to localized therapy.6 Conven-
tional imaging, namely computed tomography (CT),magnetic resonance imaging, or bone scintigraphy, are used
widely to localize recurrence and inform management after
radical therapy. However, these techniques are not without
limitations, particularly in patients with low PSA, meaning
physicians often place emphasis on risk factors rather than
negative imaging to predict probability of clinical
progression.7,8
Use of positron-emission tomography (PET) in this
setting has increased greatly in recent years. Fluo-
rodeoxyglucose PET is widely available and may detect
occult metastatic disease in certain tumors but has
limited utility in prostate cancer because of its inherently
low uptake and renal excretion obscuring local uptake.9
Choline PET/CT has superior diagnostic accuracy in
BCR compared with both conventional imaging and flu-
orodeoxyglucose.10 However, sensitivity of choline re-
mains suboptimal and its accuracy is poor in those with
low PSA and slow PSA kinetics.11,12 Investigational
prostate-specific membrane antigen (PSMA)-based PET
tracers such as 68Ga-PSMA-11 show promising results in
the BCR setting,13 but are yet to be approved in Europe
or the United States.
18F-Fluciclovine is a synthetic amino acid radiotracer that
is approved in Europe and the United States for detection of
BCR of prostate cancer on account of its established diag-
nostic performance across a wide PSA range.14-16 Here, we
evaluate the clinical benefit of 18F-fluciclovine PET/CT by
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BCR of prostate cancer under consideration for curative-
intent salvage treatment.
Methods and Materials
18F-Fluciclovine PET/CT in biochemicAL reCurrence Of
Prostate caNcer (FALCON; NCT02578940) was an open-
label study conducted at 6 UK sites that aimed to eval-
uate changes to management plans after 18F-fluciclovine
PET/CT. Secondary endpoints comprised evaluation of the
optimal PSA threshold for detecting BCR, assessment of
the outcome of salvage treatment based on whether 18F-
fluciclovine guided the plan, and safety assessment.
Each institution obtained local review board approval.
Overarching national approval and study-wide governance
review was also obtained before accrual. All patients pro-
vided written consent.
Patients
Men (age 18 years, Eastern Cooperative Oncology Group
0-2) with a first diagnosis of BCR 3 months after radical
treatment who were being considered for curative-intent
salvage therapy because of rising PSA were eligible. BCR
was diagnosed postprostatectomy as either 2 consecutive
PSA rises and a final PSA >0.1 ng/mL or 3 consecutive
PSA rises. Postprostatectomy patients were also required to
have a PSA doubling time 15 months, or a PSA level
1.0 ng/mL at relapse. In patients who had undergone
radiation therapy or brachytherapy, BCR was diagnosed as
a PSA increase of 2.0 ng/mL above nadir.
Exclusion criteria included use of androgen-deprivation
therapy (ADT) or undergoing choline PET/CT 3 months
before screening, receiving another investigational product
from 1 month before to 1 week after 18F-fluciclovine,
known 18F-fluciclovine hypersensitivity, and bilateral hip
prostheses.
Protocol
Baseline screening (blood tests, documentation of treat-
ment/imaging history, and electrocardiogram) was con-
ducted during the first visit. Intended management plans
based on pre-existing clinical information were recorded.
During visit 2, patients received routine medical screening
followed by 18F-fluciclovine PET/CT. Patients’ vital signs
and injection sites were monitored regularly for 2 hours
postinjection, and patients were discharged if no adverse
events (AEs) were observed.
At a follow-up appointment (6 weeks postscan),
clinicians recorded whether the prescan management
plan was to remain unchanged or be altered owing to
18F-fluciclovine findings. Any revisions were discussed
with the patient, and the agreed approach recorded.
Any postscan management change involving a newmodality (eg, salvage radiation therapy to systemic
therapy) was classified major, whereas changes within a
modality (eg, modified radiation therapy fields) were
classified other.
AEs, changes to clinical markers, vital signs, injection
sites, and physical examinations were assessed throughout
the study. Routine follow-up varied according to patients’
management (6 months after initiation of treatment for
non-salvage therapy [eg, ADT, watchful waiting]; until
the posttreatment PSA check [w8 months posttreatment
completion] for salvage therapy). In men receiving
salvage therapy, a treatment response was defined as a
30% decrease in PSA, stable disease as a <25%
increase or <30% decrease in PSA, and disease
progression as a 25% PSA increase from the most
recent measurement before salvage therapy to the last
reported value.
18F-Fluciclovine PET/CT
18F-Fluciclovine was manufactured by automated radio-
synthesis. The preparation of patients and 18F-fluciclovine
administration adhered to standardized procedures,17 but
in brief, patients fasted for 4 hours and refrained from
exercise for 24 hours prescan. 18F-Fluciclovine was
administered by bolus intravenous injection (370  20%
MBq) in the right arm 3 to 5 minutes before scanning.
Patients were scanned for w25 minutess in the supine
position with their arms positioned overhead, from mid-
thigh to base of skull.
Scans were interpreted at site level with readers trained
to interpret anatomic regions as positive or negative for 18F-
fluciclovine uptake according to consensus guidelines.18
Positivity rates were determined at the patient level for
the prostate/prostate bed and for extraprostatic regions
(lymph nodes, bone, or soft tissue). Investigators entered
scan findings and management plans in a standardized
manner on a centralized electronic database.
Statistics
For the primary endpoint evaluation, a required sample size
of 171 patients with complete data was estimated to allow
for 6% width in a 2-sided 95% confidence interval (CI),
based on the conservative assumption that 20% of patients
would have a treatment change.14 We aimed to recruit 180
patients, based on an anticipated 5% drop-out rate.
A single interim analysis of the primary endpoint was
preplanned for the first 85 evaluable patients with the aim
of terminating recruitment for exceeding the expected level
of efficacy if the number of treatment changes was >45
(52.9%; 97.5% CI, 40.3%-62.3%), or for futility if 8
(9.4%, 97.5% CI, 3.6%-18.9%). The interim analysis re-
ported postscan management changes for 52 out of 85
(61.2%) patients, and recruitment was stopped early owing
to the predefined criteria for efficacy being met.19
Table 1 Patient characteristics
Characteristics
Patients
N Z 104
Age, y
Median (range) 67.0 (49-81)
Mean  SD 67.5  6.80
Race, n (%)
Black 7 (6.7)
South Asian 1 (1.0)
White 93 (89)
Other 3 (2.9)
Time since initial diagnosis,
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management plans were compared, and the number, per-
centage, and exact 95% CI of patients with and without
postscan management changes were calculated. Data were
stratified by 18F-fluciclovine PET/CT result and prior treat-
ment. For the secondary analyses, the number, percentage,
and exact 95% CI of patients having a treatment response,
stable disease, and disease progression were estimated
overall and stratified by treatment received and whether a
postscan management change occurred. The point estimate
of the detection rate was estimated at regional and patient
levels for a range of baseline PSA values.•
Assessed for eligibility (N = 109)
Excluded (n = 5)
Failed screening (n = 5)
Eligible participants (n = 104)
F-Fluciclovine PET/CT (n = 104)18
Lost to follow-up (n = 1)
Reason = ‘other’ (n = 1)•
SAF (n = 104)
FAS (n = 104)
EAS (n = 104)
Fig. 1. Patient flow diagram. Abbreviations: EAS
Z evaluable analysis set, all patients from the FAS who
have an intended treatment management plan completed
and a revised management plan page completed; FAS
Z full analysis set, all patients enrolled who had 18F-
fluciclovine positron emission tomography/computed
tomography (PET/CT) at baseline; SAF Z safety
analysis set, all subjects included in the database and
who had 18F-fluciclovine administered.
mo
Median (range) 57.9 (6.3-198.9)
Mean  SD 63.1  43.0
Time since adjuvant
treatment, mo
No. adjusted 43
Median (range) 66.8 (9.2-186.9)
Mean  SD 76.2  42.8
Primary therapy, n (%)
Prostatectomy 65 (63)
With radiation therapy 5 (7.7*)
Without radiation
therapy
60 (92*)
Nonprostatectomy 39 (38)
Radiation therapy alone 16 (41y)
EBRT only 1 (2.6y)
Brachytherapy only 14 (36y)
EBRT and brachytherapy 1 (2.6y)
Radiation therapy  other
treatments
22 (56y)
EBRT and ADT 17 (44y)
Brachytherapy and ADT 2 (5.1y)
EBRT, brachytherapy and ADT 3 (7.7y)
Other treatment 1 (2.6y)
PSA, ng/mL
Whole population
Median (range) 0.79 (0.04-28.0)
Mean  SD 3.08  4.92
Patients postprostatectomy
Median (range) 0.32 (0.04-6.1)
Mean  SD 0.63  0.91
Patients postradiation
therapy (alone)
Median (range) 4.9 (1.74-28.0)
Mean  SD 7.15  6.07
Gleason scorez, n (%)
6 16 (15)
7 72 (69)
8 16 (15)
Abbreviations: ADT Z androgen deprivation therapy; EBRT Z
external beam radiation therapy; PSAZ prostate-specific antigen; SD
Z standard deviation.
* Denominator Z number of patients with prostatectomy.
y Denominator Z number of patients without prostatectomy.
z Data from biopsy (n Z 183) and surgery (n Z 150).
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Fig. 2. Regional 18F-fluciclovine detection rate. Error bars present the 95% confidence intervals. Patient-level detection
comprises any patient with a positive lesion.
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Patients
In total, 104 evaluable patients were scanned between
December 2015 and May 2017 (Fig. 1). Table 1 provides
their baseline characteristics. Approximately one-quarter of
patients had conventional imaging within the 90 days
preceding the 18F-fluciclovine PET/CT. The baseline PSA
values were recorded a mean 10.8 (median, 9; range, 1-69)
days before 18F-fluciclovine PET/CT.Imaging findings
18F-Fluciclovine-avid lesions were detected in 58 out of
104 (56%) patients, with detection rates of 44% in the
prostate/bed and 25% in extraprostatic regions (Fig. 2).
The 18F-fluciclovine detection rate generally increased
with increasing PSA (Fig. 3; Table E1, available online at0
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Fig. 3. 18F-Fluciclovine detection stratified by prostate specific
patient with a positive lesion. The “extraprostatic” bar presents p
Patient-level n presented in parenthesis on x-axis.https://doi.org/10.1016/j.ijrobp.2020.01.050). Patient-level
detection was consistently high among those with base-
line PSA >2.0 ng/mL, with 93% of patients showing a
positive result above this threshold. Lymph node and
skeletal positivity ranged from 8.9% and 3.6%,
respectively, at PSA 1 ng/mL to 50% and 13%,
respectively, at >10 ng/mL.Therapeutic management
As presented in Figure 4 (left-hand side), the most common
prescan management plan was salvage radiation therapy
(n Z 65, 62%; 16 of whom had adjuvant ADT). Most of
the prescan plans for radiation therapy were to target the
prostate bed (n Z 57 [88%], 16 with adjuvant ADT), with
the remainder focusing on the prostate bed and whole
pelvis or with a boost determined by conventional imaging.
In total, 28 (27%) patients had a prescan plan for salvage
brachytherapy (3 with adjuvant ADT), 6 (6%) were0−2.0
 = 5)
> 2.0−5.0
(n = 24)
> 5.0−10.0
(n = 11)
> 10.0
(n = 8)
ng/mL
ed Extraprostatic
antigen (PSA) level. Patient-level detection comprises any
ositivity in lymph nodes, soft tissues/parenchyma and bone.
Salvage radiotherapy to prostate bed with boost to fluciclovine-positive areas (+ ADT)
Salvage radiotherapy to prostate bed
Salvage radiotherapy to prostate bed with boost to fluciclovine-positive areas
Salvage radiotherapy to prostate bed
Salvage radiotherapy to prostate bed (+ ADT)
Salvage radiotherapy to prostate bed and whole pelvis
Salvage radiotherapy to prostate bed and whole pelvis with boost based on conventional imaging
Salvage prostatectomy (+ ADT)
Salvage brachytherapy 
Salvage brachytherapy (+ ADT)
Salvage prostatectomy
Salvage prostatectomy + lymphadenectomy
Salvage radiotherapy to prostate bed with boost based on conventional imaging
Salvage radiotherapy to prostate bed with boost based on conventional imaging
Salvage radiotherapy to prostate bed and whole pelvis (+ ADT)
Pelvis lymph node radiotherapy (+ ADT)
Brachytherapy
Salvage radiotherapy to prostate bed (+ ADT) 
Chemotherapy (+ ADT) 
SABR (+ ADT) 
HIFU (+ ADT) 
HIFU (+ ADT) 
Pelvic lymph node radiotherapy
Watchful waiting
Salvage branchytherapy guided by fluciclovine
ADT
Cystoscopy
Fig. 4. Sankey diagram to show changes in management for all 104 patients from prescan plans (left) to postscan plans
(right). Abbreviation: androgen deprivation therapy.
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ADT), and 5 (5%) had a prescan plan for high-intensity
focused ultrasound (HIFU) plus ADT.
After the 18F-fluciclovine PET/CT, plans were revised
for 66 out of 104 (63%) patients; 6% (4 out of 66) of these
revisions occurred owing to incidental findings (eg, recur-
rence of melanoma, further evaluation of a lung nodule).
Figure 4 depicts the changes to management plans.
Forty-three of the 66 postscan management changes
(65%) were classified major. Most frequently these were
from salvage therapy to systemic therapy (16 out of 66) or
watchful waiting (16 out of 66), accounting for 32 out of
104 (31%) patients and 48% (32 out of 66) of all changes.
Of the 16 patients who had management revised from
salvage therapy to noncurative systemic therapy (7 from
brachytherapy [1 with ADT], 6 from radiation therapy, 2
from prostatectomy, and 1 from HIFU with ADT), 13
(81%) had positive scans, often with distant metastases (eg,
extrapelvic lymph nodes [n Z 9] or skeletal metastasis [n
Z 4]). In total, 9 patients scheduled for salvage radiation
therapy (5 with ADT), 2 for salvage brachytherapy, 3 for
prostatectomy (2 with ADT), and 2 for HIFU with adjuvant
ADT had their plans revised to watchful waiting; most of
these patients had a negative scan result (10 out of 16,63%). The remaining 11 out of 66 (17%) major changes
(all of which were after positive scans) commonly included
the introduction of chemotherapy or removal of ADT from
a dual-modality approach in favor of monotherapy.
The remaining management changes were all modifi-
cations of prescan plans (23 of 66, 35%). These were re-
visions to plans for salvage radiation therapy to the prostate
bed (n Z 8) to include a boost to 18F-fluciclovine-avid
lesions or for salvage brachytherapy (nZ 14) to be guided
by 18F-fluciclovine. One additional patient who had a
positive scan result had planned brachytherapy modified to
allow findings from cystoscopy to be considered.
Both positive and negative 18F-fluciclovine results
influenced plans, but the majority of patients with a revised
plan had positive results (53 out of 66, 80%). In contrast,
87% (33 out of 38) of patients with no postscan revision
had negative scans. Of all enrolled patients, more than half
had management changes because of a positive 18F-fluci-
clovine scan (53 out of 104, 51%). Among 58 patients with
a positive scan, the most frequent major change was from
salvage therapy to systemic therapy (13 out of 58, 22.4%).
In this group, almost all (12 out of 13) were upstaged
because 18F-fluciclovine indicated metastases outside the
prostate/bed.
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Ultimately, 56 patients (54%) received salvage therapy,
whether in line with proposed revised plans or not. In the
17 patients who received 18F-fluciclovine-guided salvage
treatment, either radiation therapy to the prostate bed with
boost to areas guided by 18F-fluciclovine (n Z 7) or 18F-
fluciclovine-guided brachytherapy (n Z 10), 15 out of 17
(88%) had a treatment response. Where 18F-fluciclovine
PET/CT did not influence delivery of salvage treatment
(n Z 39), 28 (72%) patients showed a response.
Safety
In total, 27 (26.0%) patients experienced a total of 38
treatment-emergent AEs. Of these, 8 (7.7%) patients had
events possibly related to 18F-fluciclovine. These were
headache (4 patients; 1 grade 2 and 3 grade 1); 2 events
each of grade 1 fatigue, dizziness, and dysgeusia; 1 grade 1
event of parosmia; 1 grade 1 tremor; 1 grade 1 increase in
blood creatine phosphokinase; and 1 grade 1 erythema. One
patient had a grade 1 injection site erythema that was
considered definitely related to 18F-fluciclovine.
Discussion
Since 2013, UK evidence-based intercollegiate guidelines
have recommended PET/CT for patients suspected to have
BCR where results would directly influence management,20
but current UK National Institute for Health and Care
Excellence guidelines do not discuss advanced imaging for
asymptomatic patients.21 The latest EAU guidelines, how-
ever, recommend PSMA PET/CT for patients with BCR at
PSA levels as low as >0.2 ng/mL in patients who have
undergone radical prostatectomy if the results will influ-
ence treatment decisions. A recommendation specifically
for 18F-fluciclovine is included for posteradiation therapy
patients or for those posteradical prostatectomy with PSA
1 ng/mL where PSMA PET/CT is not available.3 US
National Comprehensive Cancer Network guidelines also
recommend 18F-fluciclovine in the workup of patients with
recurrence of prostate cancer.22
Our prospective data demonstrate that 18F-fluciclovine
PET/CT yields detection of prostatic and extraprostatic le-
sions across a wide range of PSA levels; even below the
EAU-advised 1 ng/mL threshold, approximately one-third
of patients had positive scans. Our cohort comprised a
mix of postprostatectomy and posteradiation therapy
patients and had an overall median PSA of 0.79 ng/mL, or
0.32 ng/mL when only postprostatectomy patients are
considered. Nevertheless, the majority of our cohortdwho
were still considered out of scope according to current EAU
guidelinesdhad a management change because of 18F-
fluciclovine.
Previous studies have demonstrated the ability of 18F-
fluciclovine to influence management, including US-based18F Fluciclovine (FACBC) PET/CT in Patients with Ris-
ing PSA after Initial Prostate Cancer Treatment (LOCATE),
which reported results very similar to the present study
(patient-level detection of 57% with overall 59% manage-
ment changes, compared with 56% and 63%, respec-
tively).23 The present study confirms and extends prior
findings that both positive and negative results influence
management. As might be expected, positive results were
more likely to influence plans. The most common major
change after a positive 18F-fluciclovine result was from
salvage therapy to systemic therapy. Nearly all (92%) of
such patients showed metastases outside the prostate or
prostate bed, suggesting 18F-fluciclovine PET/CT may
provide critical information to inform the appropriateness
of salvage therapy and potentially avoid futile salvage
treatment in those with extraprostatic disease.
In line with previous studies, we show 18F-fluciclovine
PET/CT can refine planned therapy through localization of
disease.24,25 Here, almost one-quarter of patients and 42%
of those with a positive result had their prescan plan for
salvage radiation therapy or brachytherapy modified. The
potential success of this decision is shown by the secondary
analysis of patients ultimately receiving salvage therapy. A
higher rate of PSA response was observed in patients who
received 18F-fluciclovine-guided salvage brachytherapy or
radiation therapy with boosts, compared with those who
received salvage therapy without added guidance by 18F-
fluciclovine. It is important to note that the study was not
powered to directly evaluate differences in PSA response
between these groups, and the results are based on short-
term PSA responses, bearing limited translational signifi-
cance. Nonetheless, a trend of higher response rates in the
former group hints at the potential for more sensitive im-
aging to direct both development and implementation of
salvage approaches.
Although the majority of revised management followed
positive scans, with a new imaging agent establishing
confidence in negative results is paramount; we show
20% of revisions occurred despite negative results. These
were predominantly changes from salvage therapy to
watchful waiting, which is consistent with findings from
LOCATE.23 This confirms that negative 18F-fluciclovine
results were interpreted in the knowledge of 8F-fluciclo-
vine’s established histologically confirmed performance16
and suggests that patients may have avoided therapy
that would otherwise be futile or significantly affect their
quality of life.
Prospective studies published after the initiation of the
present trial report that alternative radiotracers also affect
management; both choline- and 68Ga-PSMA-11 directed
management changes forw50% of patients,26-28 similar to
the results here with 18F-fluciclovine. 18F-Fluciclovine,
however, offers numerous notable benefits over these
counterparts; 18F-fluciclovine yields better detection
than choline and does not display the limited utility at
low PSA associated with choline.12,15,16 Two recent
studies have prospectively compared the performance of
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18F-fluciclovine and 68Ga-PSMA with interesting find-
ings.29,30 Although Calais et al29 reported 68Ga-PSMA-11
to achieve higher overall detection (56%) than 18F-fluci-
clovine (26%) in a single-center, low-PSA cohort (< 2 ng/
mL), Pernthaler et al30 reported less variation between the
detection rates achieved with 68Ga-PSMA-11 (82.8 %) and
18F-fluciclovine (79.3%). Pernthaler’s cohort had a wider
PSA range (median 4.1 ng/mL) than Calais’; however,
when limiting to only those patients with a PSA 2 ng/mL,
detection rates for 68Ga-PSMA-11 and 18F-fluciclovine
were still less varied (53% vs 42%, respectively) than in the
Calais study.31 Moreover, in contrast with PSMA-based
tracers, 18F-fluciclovine is already approved in Europe
and the United States in this indication. Data from a recent
costeconsequence study also suggest that 18F-fluciclovine
use for patients with BCR may result in better clinical
outcomes while remaining relatively cost neutral.32
Additionally, as we show here 18F-fluciclovine is well
tolerated, with less than 10% of patients experiencing a
related AE, the majority of which were mild.
A limitation of the present study is the lack of confirma-
tion of imaging with histologic findings; however, the diag-
nostic performance of 18F-fluciclovine PET/CT has been
verified.16 In addition, because improved outcomes are not
guaranteed from management changes, additional longer-
term follow-up is required to fully establish the benefit of
18F-fluciclovine PET/CT in patients. Currently, a number of
prospective phase 2/3 studies are underway that may offer
valuable insights: NCT01666808, NCT03582774,
NCT03762759, and NCT03525288 aim to determine the
effect of 18F-fluciclovine or PSMAPET/CT-guided radiation
therapy plans on longer-term disease outcomes.
Another limitation is the lack of requirement for nega-
tive conventional imaging before inclusion in the study.
Only around one-quarter of patients had conventional im-
aging within the 90 days preceding PET/CT. However, we
are reassured of the positive effect of 18F-fluciclovine PET/
CT on management plans by the findings from the US-
based study, LOCATE, which was conducted in 213 pa-
tients, all of whom had negative or equivocal conventional
imaging a median of 30 days before 18F-fluciclovine PET/
CT.23 The proportion of patients experiencing a change in
management plan after 18F-fluciclovine imaging reported
by LOCATE was in line with our study.Conclusions
The present study in which the majority of patients had
their treatment plans modified after 18F-fluciclovine PET/
CT demonstrates the potential for 18F-fluciclovine in stag-
ing patients with BCR of prostate cancer at PSA levels
below thresholds where imaging is currently advocated by
guidelines. Reliable localization of lesions with 18F-fluci-
clovine PET/CT in patients with BCR of prostate cancer
may help determine the most appropriate treatment
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